Matt Morgan joined Hull York Medical School in February 2020 as Deputy Dean and Professor of Renal Medicine and Medical Education.As Deputy Dean he supports the Dean in the strategic development and delivery of the Medical School.
Matt completed his undergraduate training in Birmingham and postgraduate training in the West Midlands. He worked as Clinical Senior Lecturer in Renal Medicine at the University of Birmingham and Honorary Consultant Nephrologist at University Hospitals Birmingham NHS Foundation Trust from 2009. His main clinical and research interests have been in the field of ANCA vasculitis and inflammatory renal disease.
Matt will be setting up a dedicated vasculitis clinic as an Honorary Consultant Nephrologist at Hull University Teaching Hospitals NHS Trust. Matt is a Fellow of the Royal College of Physicians.
Matt’s research has focused on improving care for people with ANCA vasculitis (Wegener’s granulomatosis/granulomatosis with polyangiitis, microscopic polyangiitis and Churg-Strauss Syndrome/eosinophilic granulomatosis with polyangiitis) through understanding the pathogenesis of the diseases and trialling new treatments. Matt has also worked with Vasculitis UK, the UK’s leading support group for people with vasculitis as the lead author of the Vasculitis Routemap and the patient information content of their website (https://www.vasculitis.org.uk/).
Matt has wide experience in both undergraduate and postgraduate medical and allied health profession education having been both a year lead and Deputy Programme Director for the MB ChB programme in Birmingham, part of the team setting up a new MPharm programme and teaching across a wide variety of undergraduate and postgraduate courses and postgraduate medical training. Matt is a Fellow of the Higher Education Academy.
Matt has also been active in promoting diversity and inclusion in healthcare and healthcare education through his roles as LGBT+ staff network chair at Queen Elizabeth Hospital Birmingham, membership of equality, diversity and inclusion committees, leading on work to understand student experience of bullying, discrimination and unprofessional behaviour in clinical placements and LGBT+ student mentor.
View Matt's full Publication List: https://orcid.org/0000-0002-7831-2245
Google Scholar: https://scholar.google.co.uk/citations?hl=en&user=va2ic98AAAAJ
ResearchGate Account: https://www.researchgate.net/profile/Matthew_Morgan11
1. Chanouzas D, McGregor JAG, Nightingale P, Salama AD, Szpirt WM, Basu N, Morgan MD, Poulton CJ, Draibe JB, Krarup E, Dospinescu P, Dale JA, Pendergraft WF, Lee K, Egfjord M, Hogan SL, Harper L. Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study. BMC Nephrol. 2019 Feb 18;20(1):58. doi: 10.1186/s12882-019-1226-0
2. Harper L, Morgan MD, Chanouzas D, Caulfield HK, Coughlan L, Dean C, Fletcher K, Cramp F, Greenfield S, Hewitt CA, Ives NJ, Jowett S, Daley A. Treatment of fatigue with physical activity and behavioural change support in vasculitis: study protocol for an open-label randomised controlled feasibility study. BMJ Open. 2018 Oct 30;8(10):e023769. doi: 10.1136/bmjopen-2018-023769.
3. Chanouzas D, Sagmeister M, Dyall L, Sharp P, Powley L, Johal S, Bowen J, Nightingale P, Ferro CJ, Morgan MD, Moss P, Harper L. The host cellular immune response to cytomegalovirus targets the endothelium and is associated with increased arterial stiffness in ANCA-associated vasculitis. Arthritis Research and Therapy in press.
4. Chanouzas D, Sagmeister M, Faustini S, Nightingale P, Richter A, Ferro CJ, Morgan MD, Moss P, Harper L. Subclinical reactivation of cytomegalovirus drives CD4+CD28null T-cell expansion and impaired immune response to pneumococcal vaccination in ANCA-associated vasculitis. J Infect Dis 2018. https://doi.org/10.1093/infdis/jiy493
5. Wall NA, Dominguez-Medina CC, Faustini SE, Cook CN, McClean A, Jesky MD, Perez-Toledo M, Morgan MD, Richter AG, Ferro CJ, Cockwell P, Moss PA, Henderson IR, Harper L, Cunningham AF. Humoral immunity to memory antigens and pathogens is maintained in patients with chronic kidney disease. PLoS One. 2018 Apr 16;13(4):e0195730. doi: 10.1371/journal.pone.0195730.
6. Maybury C, Morgan MD, Smith R, Harper L. How does the outcome of research training fellowships funded via the NHS compare with that from competitively funded fellowships from the MRC and other charities: a cross-sectional retrospective survey of trainees undertaking research training in the West Midlands. BMJ Open. 2018 Jan 23;8(1):e019630. doi: 10.1136/bmjopen-2017-019630
7. Morgan MD, Szeto M, Walsh M, Jayne D, Westman K, Rasmussen N, Hiemstra TF, Flossmann O, Berden A, Höglund P, Harper L; European Vasculitis Society. Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse. Arthritis Res Ther. 2017 Jun 7;19(1):129. doi: 10.1186/s13075-017-1321-1.
8. Chanouzas D, Dyall L, Nightingale P, Ferro C, Moss P, Morgan MD, Harper L. Valaciclovir to prevent Cytomegalovirus mediated adverse modulation of the immune system in ANCA-associated vasculitis (CANVAS): study protocol for a randomised controlled trial. Trials (2016) 17:338. DOI 10.1186/s13063-016-1482-2
9. McClean A*, Morgan MD*, Basu N, Bosch JA, Nightingale P, Jones D, Harper L. Physical Fatigue, Fitness and Muscle Function in Patients with Anti-neutrophil Cytoplasm Antibody-Associated Vasculitis. Arthritis Care Res 2015 DOI: 10.1002/acr.22827
*Joint first authors
10. Morgan MD, Richter A, Al-Ali S, Flint J, Yiannakis C, Drayson M, Goldblatt D, Harper L. Low B cells and IgG are associated with infection, while poor vaccine response predicts all-cause mortality in an immunosuppressed vasculitis population. Arthritis Care Res 2015 doi: 10.1002/acr.22757